Verofenib Vemurafenib tablets 240mg/tablet, 56 tablets/box

Medication Safety Tips

Use this product according to its instructions, medical advice, and your health needs. Shipping is arranged after payment once the order meets dispatch requirements.

Contraindications

Warnings and Precautions
1. New or primary skin malignancies: Dermatological assessment is performed every 2 months before and during treatment and up to 6 months after discontinuation of LuciVemu. Continue treatment after resection without dose adjustment.
2. New noncutaneous squamous cell carcinoma: Regularly assess the symptoms or clinical signs of new noncutaneous squamous cell carcinoma before and during treatment.
3. Other malignancies: Closely monitor patients receiving LuciVemu for signs or symptoms of other malignancies.
4. Tumor promotion of BRAF wild-type melanoma: BRAF inhibitors can increase cell proliferation.
5. Serious hypersensitivity reactions, including allergic reactions and drug reactions, with eosinophilia and systemic symptoms (dress syndrome): serious hypersensitivity adverse reactions discontinue LuciVemu.
6. Severe skin reaction, including Stevens-Johnson syndrome and toxic epidermal necrolysis: patients with severe skin disease should stop taking LuciVemu.
7. Prolonged QT interval: electrocardiogram and electrolytes are monitored before and during treatment. Pause LuciVemu when QTc reaches or exceeds 500 milliseconds. Correct electrolyte abnormalities and control cardiac risk factors for prolonged QT intervals.
8. Hepatotoxicity: Detect liver enzymes and bilirubin before starting LuciVemu treatment and monitor monthly during treatment.
9. Photosensitivity: It is recommended that patients avoid sun exposure.
10. Severe ophthalmic reactions: Monitor the signs and symptoms of uveitis.
11. Embryo-fetal toxicity: May cause harm to the fetus. Inform women of potential fetal risks and use effective contraception.
12. Radiation sensitization and radiation recall: Serious cases have been reported.
13. Renal failure: Measure serum creatinine before starting LuciVemu and monitor regularly during treatment.
14. Palmar aponeurosis and plantar fasciofibromatosis: Events should be managed by dose reduction, treatment interruption, or treatment discontinuation.

Medication risks

Adverse Reactions
Melanoma: The most common adverse reactions (≥ 30%) are arthralgia, rash, hair loss, fatigue, photosensitivity, nausea, itching, and cutaneous papilloma.
Erdheim-Chester disease: The most common adverse reactions (> 50%) are arthralgia, rash, maculo-papular rash, alopecia, fatigue, prolonged electrocardiogram QT interval, and cutaneous papilloma.

【Drug interactions】
Avoid concomitant administration of LuciVemu with potent CYP3A4 inhibitors or inducers.
CYP1A2 Substrate: LuciVemu can increase the concentration of the CYP1A2 matrix. Avoid using both LuciVemu and CYP1A2 substrates within a short treatment window. If co-administration cannot be avoided, monitor the toxicity closely and consider reducing the dose of the CYP1A2 substrate.